As Alzheimer’s disease and other forms of dementia continue to become more prevalent, it may not be long before there is a push for legalizing physician-assisted death in dementia cases in the United States. American officials must thoroughly consider the moral and social consequences of such an action, says an expert on medical ethics at Washington University in St. Louis.
More than half of older adults with clinical depression don’t get better when treated with an antidepressant. But results from a multicenter clinical trial that included Washington University School of Medicine in St. Louis indicates that adding a second drug — an antipsychotic medication — to the treatment regimen helps many of those patients.
Discovering ways to honor the dignity of individuals coping with Alzheimer’s disease and other dementias is the goal of an interdisciplinary symposium on “Finding Humanity in Advanced Dementia” to be held in Wilson Hall on the Danforth Campus of Washington University in St Louis on Saturday, April 27.
Sleep is disrupted in people who likely have early Alzheimer’s disease but do not yet have the memory loss or other cognitive problems characteristic of full-blown disease, researchers at the School of Medicine report. Shown is first author of the study, Yo-El Ju, MD, an assistant professor of neurology.
Researchers at Washington University School of Medicine in St. Louis have found a key difference in the brains of people with Alzheimer’s disease and those who are cognitively normal but still have the brain plaques that characterize this type of dementia.
Sleep disruptions may be among the earliest indicators of the start of Alzheimer’s disease, scientists at Washington University School of Medicine in St. Louis report this week in Science Translational Medicine. David M. Holtzman, MD, the Andrew B. and Gretchen P. Jones Professor and head of the Department of Neurology, is the study’s author.
Emergency physician Chris Carpenter, MD, is conducting a study of patients in the emergency room who are older than 65 and at increased risk of having dementia. He wants to determine if referring suspected Alzheimer’s patients to an outreach agency will reduce frequent returns to the emergency department and help them remain independent longer.
A new marker of Alzheimer’s disease can predict how rapidly a patient’s memory and other mental abilities will decline after the disorder is diagnosed, Rawan Tarawneh, MD, found while a postdoctoral research associate at Washington University School of Medicine in St. Louis. The new data suggest that VILIP-1 potentially may be a better predictor of Alzheimer’s progression than other markers.
Studying family members suspected of having Alzheimer’s disease, researchers at Washington University School of Medicine in St. Louis have identified a gene that causes a rare disorder highlighted by memory loss and motor impairments. The condition is known as Kufs disease, but scientists say the discovery paves the way to development of a genetic test for Kufs and to therapies to treat dementia, which is a hallmark of Kufs and of other neurodegenerative conditions, such as Alzheimer’s disease.
In a marriage of two disciplines that don’t often overlap — politics and medicine — a study by Matthew Gabel, PhD, professor of political science in Arts & Sciences at Washington University in St. Louis, finds that group consensus is an effective method for diagnosing Alzheimer’s disease.